2229 related articles for article (PubMed ID: 27459230)
1. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.
Rosenfield RL; Ehrmann DA
Endocr Rev; 2016 Oct; 37(5):467-520. PubMed ID: 27459230
[TBL] [Abstract][Full Text] [Related]
2. The Polycystic Ovary Morphology-Polycystic Ovary Syndrome Spectrum.
Rosenfield RL
J Pediatr Adolesc Gynecol; 2015 Dec; 28(6):412-9. PubMed ID: 25840648
[TBL] [Abstract][Full Text] [Related]
3. Current concepts of polycystic ovary syndrome.
Rosenfield RL
Baillieres Clin Obstet Gynaecol; 1997 Jun; 11(2):307-33. PubMed ID: 9536213
[TBL] [Abstract][Full Text] [Related]
4. 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome.
Pasquali R; Patton L; Pocognoli P; Cognigni GE; Gambineri A
J Clin Endocrinol Metab; 2007 Nov; 92(11):4208-17. PubMed ID: 17785360
[TBL] [Abstract][Full Text] [Related]
5. Adipocyte and steroidogenic cell cross-talk in polycystic ovary syndrome.
de Medeiros SF; Rodgers RJ; Norman RJ
Hum Reprod Update; 2021 Jun; 27(4):771-796. PubMed ID: 33764457
[TBL] [Abstract][Full Text] [Related]
6. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
7. Characterization of reproductive, metabolic, and endocrine features of polycystic ovary syndrome in female hyperandrogenic mouse models.
Caldwell AS; Middleton LJ; Jimenez M; Desai R; McMahon AC; Allan CM; Handelsman DJ; Walters KA
Endocrinology; 2014 Aug; 155(8):3146-59. PubMed ID: 24877633
[TBL] [Abstract][Full Text] [Related]
8. Basal insulin-like factor 3 levels predict functional ovarian hyperandrogenism in the polycystic ovary syndrome.
Gambineri A; Patton L; Prontera O; Fanelli F; Ciampaglia W; Cognigni GE; Pagotto U; Pasquali R
J Endocrinol Invest; 2011 Oct; 34(9):685-91. PubMed ID: 21586896
[TBL] [Abstract][Full Text] [Related]
9. Source localization of androgen excess in adolescent girls.
Ibáñez L; Potau N; Zampolli M; Prat N; Gussinyé M; Saenger P; Vicens-Calvet E; Carrascosa A
J Clin Endocrinol Metab; 1994 Dec; 79(6):1778-84. PubMed ID: 7989484
[TBL] [Abstract][Full Text] [Related]
10. Review: fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies.
Xita N; Tsatsoulis A
J Clin Endocrinol Metab; 2006 May; 91(5):1660-6. PubMed ID: 16522691
[TBL] [Abstract][Full Text] [Related]
11. Insulin and hyperandrogenism in women with polycystic ovary syndrome.
Baptiste CG; Battista MC; Trottier A; Baillargeon JP
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):42-52. PubMed ID: 20036327
[TBL] [Abstract][Full Text] [Related]
12. Adolescent polycystic ovary syndrome due to functional ovarian hyperandrogenism persists into adulthood.
Rosenfield RL; Ehrmann DA; Littlejohn EE
J Clin Endocrinol Metab; 2015 Apr; 100(4):1537-43. PubMed ID: 25675386
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome and insulin-resistant hyperinsulinemia.
Rosenfield RL
J Am Acad Dermatol; 2001 Sep; 45(3 Suppl):S95-104. PubMed ID: 11511859
[TBL] [Abstract][Full Text] [Related]
14. [Genetic aspects of polycystic ovary syndrome].
Jakubowski L
Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
[TBL] [Abstract][Full Text] [Related]
15. Obesity and the polycystic ovary syndrome.
Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
[TBL] [Abstract][Full Text] [Related]
16. The risk of functional ovarian hyperandrogenism and polycystic ovary syndrome in patients with hyperandrogenism.
Cetinkaya E; Ocal G; Berberoğlu M; Adiyaman P
J Pediatr Endocrinol Metab; 2003 Sep; 16(7):1011-6. PubMed ID: 14513878
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
[TBL] [Abstract][Full Text] [Related]
18. Steroid metabolome profiling of follicular fluid in normo- and hyperandrogenic women with polycystic ovary syndrome.
Yang Z; Zhou W; Zhou C; Zhou Y; Liu X; Ding G; Hu Y; Pan J; Sheng J; Jin L; Huang H
J Steroid Biochem Mol Biol; 2021 Feb; 206():105806. PubMed ID: 33340681
[TBL] [Abstract][Full Text] [Related]
19. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction.
González F
Semin Reprod Med; 2015 Jul; 33(4):276-86. PubMed ID: 26132932
[TBL] [Abstract][Full Text] [Related]
20. Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome.
Barnes RB
Semin Reprod Endocrinol; 1997 May; 15(2):159-68. PubMed ID: 9165659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
